Forgot Password?
Return to Course Listing

CME: Pediatric Crohn's disease: Therapeutic updates and optimizing treatment

ACCREDITATION EXPIRED: May 24, 2021

Activity Description / Statement of Need:

In this online CME self-learning program:

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that is defined by a transmural process that often occurs in the terminal ileum but may occur in any portion of the GI tract. Although the exact etiology of CD is unknown, a handful of genetic, immunological, and environmental risk factors have been identified. Research suggests that in genetically susceptible patients, there is an impaired immune response to commensal or pathogenic intestinal microbiota that drives mucosal inflammation. The incidence of pediatric CD (pCD) is increasing around the globe, varying between 2.5 to 11.4 per 100,000, with an estimated prevalence of 58 per 100,000. Approximately 25% of patients are diagnosed with IBD before the age of 18. Intestinal and abdominal complications such as strictures, abscesses, and fistulas are common among pediatric patients and increase as the disease progresses. IBD impairs attendance at school, and psychosocial ramifications in children diagnosed with IBD incdude a higher incidence of depression and anxiety.

 

Target Audience:

The following healthcare professionals: pediatricians and pediatric gastroenterologists; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who clinically encounter patients with pCD.

This program is supported by an educational grant from Abbott Nutrition.

This activity is free of charge.

Release Date: May 24, 2019 -- Expiration Date: May 24, 2021

Faculty: Dinesh Pashankar, MD

Agenda

Epidemiology and clinical features of pCD

  • Statistics by severity
  • Causes and risk factors
  • Clinical features: endoscopic, radiologic, and histopathologic

Treatment of pCD

  • Societal diagnostic guidance in pCD
  • Nutritional intervention and treatment protocols
  • EN (including tube-feeding) and parenteral nutrition, where applicable
  • Medications for induction and maintenance therapy for pCD: salicylates, including novel formulations; glucocorticoids; immunomodulators; biologicals (e.g., infliximab, adalimumab) 
  • Therapies and approaches under investigation in the treatment of pCD disease: etrolizumab; vedolizumab; extracorporeal photopheresis 
  • Adherence to therapy and modifiable factors that may exacerbate the disease course 
  • The role of teaching and communication strategies in strengthening the patient-provider compact 
  • Patient case(s) 

Learning Objectives

By the end of the session the participant will be able to:

  • Describe differences between European and American approaches to pCD
  • Identify the present nutritional and pharmacotherapeutic treatment options currently available for management of pCD and apply them to patient cases using evidence-based medicine
  • Identify new and emerging approaches to and therapies for the treatment of pCD
  • Evaluate a treatment plan for a specific patient based on severity of pCD to optimize safety and efficacy, suggesting modifications for improvement

Accreditation

ACCME Activity #201336468

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Dinesh S. Pashankar, MD, discloses financial support (research grant) from Janssen and Abbvie.

Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by an educational grant from Abbott Nutrition.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Medical and nutritional management of eosinophilic esophagitis in adolescents and adults: Therapeutic updates and best practices

The current and emerging landscape of pediatric growth hormone deficiency (GHD) pharmacotherapy

The Current and Emerging Landscape of Pharmacotherapy for Neonatal Respiratory Distress Syndrome (NRDS)

Treatment strategies in Hunter Syndrome